Iohexol
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1985
- First approval year
- 1985
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Iohexol
- Molecular weight
- 821.14
- Structure (SMILES)
- CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I
- exypaque
- Exypaque
- omnipaque
- Omnipaque
- omnipaque 12
- Omnipaque 12
- omnipaque 140
- Omnipaque 140
- omnipaque 180
- Omnipaque 180
- omnipaque 210
- Omnipaque 210
- omnipaque 240
- Omnipaque 240
- omnipaque 300
- Omnipaque 300
- omnipaque 350
- Omnipaque 350
- omnipaque 70
- Omnipaque 70
- omnipaque 9
- Omnipaque 9
- oraltag
- Oraltag
- 1 3 benzenedicarboxamide 5 acetyl 2 3 dihydroxypropyl amino n n bis 2 3 dihydroxypropyl 2 4 6 triiodo
- 1,3-BENZENEDICARBOXAMIDE, 5-(ACETYL(2,3-DIHYDROXYPROPYL)AMINO)-N,N'-BIS(2,3-DIHYDROXYPROPYL)-2,4,6-TRIIODO
- 15 40 ml of dye iohexol as contrast
- Iodinated Contrast Agent (Omnipaque)
- iodinated contrast agent omnipaque
- iohexol
- Iohexol
- IOHEXOL
- IOHEXOL [EP IMPURITY]
- IOHEXOL [EP MONOGRAPH]
- iohexol [INN]
- IOHEXOL [JAN]
- IOHEXOL [MART.]
- IOHEXOL [MI]
- IOHEXOL [ORANGE BOOK]
- IOHEXOL [USAN]
- IOHEXOL [USP MONOGRAPH]
- IOHEXOL [USP-RS]
- IOHEXOL [VANDF]
- Iohexol [WHO-DD]
- IOHEXOL [WHO-IP]
- iohexol ep impurity
- iohexol ep monograph
- iohexol injection
- Iohexol Injection
And 31 more, listed on the interactive page.
- ATC classification codes
- V08AB02
Sources for recorded values
- CAS registry numbers
- 66108-95-0
- ChEMBL ID
- CHEMBL1200455
- InChIKey
- NTHXOOBQLCIOLC-UHFFFAOYSA-N
- PubChem compound IDs
- 3730
- RxNorm IDs (RxCUI)
- 5956
- FDA ingredient codes (UNII)
- 4419T9MX03
- Applicant
- GE HEALTHCARE
- Approval date
- 26 Dec 1985
- Application number
- NDA018956
- Patents
- 0
- Designations
- 0
- Earliest recorded loss of exclusivity
- 26 Jul 2026
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- United States (FDA)
- Approved
- Drug name stem
- io-
Administration routes
- Oral
- Parenteral
- topical
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- HIV Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Kidney Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Myocardial Ischemia
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001375
- Subject identifier
- D017202
- Condition
- Renal Insufficiency
- Highest recorded phase
- 1
- Condition identifier
- HP:0000083
- Subject identifier
- D051437
- Condition
- Acute Kidney Injury
- Highest recorded phase
- 2
- Condition identifier
- HP:0001919
- Subject identifier
- D058186
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Breast Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Fabry Disease
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0010526
- Subject identifier
- D000795
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001375
- Highest recorded phase
- 3
- Condition identifier
- HP_0000083
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002492
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005147
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005575
- Condition identifier
- MONDO_0010526
- Highest recorded phase
- 1
Warnings
- Warning
- Black Box Warning
- Effect
- misuse
Open Targets warnings
- Warning
- Black Box Warning
- Effect
- misuse
- Country
- United States
- Event
- anaphylactic reaction
- Reports
- 146
- Reporting signal score
- 160.319
- Event
- anaphylactic shock
- Reports
- 105
- Reporting signal score
- 169.231
- Event
- anaphylactoid reaction
- Reports
- 82
- Reporting signal score
- 228.828
- Event
- anaphylactoid shock
- Reports
- 28
- Reporting signal score
- 104.876
- Event
- blood pressure decreased
- Reports
- 105
- Reporting signal score
- 106.711
- Event
- cardio-respiratory arrest
- Reports
- 36
- Reporting signal score
- 52.5549
- Event
- chest discomfort
- Reports
- 134
- Reporting signal score
- 113.106
- Event
- chills
- Reports
- 192
- Reporting signal score
- 192.6
- Event
- contrast media allergy
- Reports
- 100
- Reporting signal score
- 430.232
- Event
- contrast media reaction
- Reports
- 175
- Reporting signal score
- 753.508
- Event
- cough
- Reports
- 169
- Reporting signal score
- 61.5372
- Event
- diarrhoea
- Reports
- 32
- Reporting signal score
- 77.4048
- Event
- drug reaction with eosinophilia and systemic symptoms
- Reports
- 59
- Reporting signal score
- 50.1588
- Event
- dyspnoea
- Reports
- 437
- Reporting signal score
- 206.879
- Event
- erythema
- Reports
- 435
- Reporting signal score
- 632.414
- Event
- extravasation
- Reports
- 128
- Reporting signal score
- 389.349
- Event
- eye pruritus
- Reports
- 50
- Reporting signal score
- 72.2687
- Event
- eye swelling
- Reports
- 66
- Reporting signal score
- 88.2167
- Event
- eyelid oedema
- Reports
- 43
- Reporting signal score
- 60.4618
- Event
- fall
- Reports
- 14
- Reporting signal score
- 46.6022
- Event
- fatigue
- Reports
- 38
- Reporting signal score
- 78.2147
- Event
- generalised erythema
- Reports
- 34
- Reporting signal score
- 57.3491
- Event
- hypersensitivity
- Reports
- 201
- Reporting signal score
- 148.347
- Event
- infusion site extravasation
- Reports
- 31
- Reporting signal score
- 52.7323
- Event
- injection site extravasation
- Reports
- 37
- Reporting signal score
- 51.7372
And 24 more, listed on the interactive page.
- NCT01214993
- NCT01839526
- NCT01984411
- NCT02772276
- NCT03545087
- NCT03997370
- NCT04199754
- NCT04504331
- NCT05754749
- NCT04627831
- Hydrogen bond acceptors
- 9
- Hydrogen bond donors
- 8
- Polar surface area
- 199.89
- Calculated partition coefficient (ALogP)
- -1.63
- Calculated partition coefficient (XLogP)
- -3
- Prodrug
- No
- Chirality
- Racemic
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 12
- Heavy atoms
- 34
- Molecular formula
- C19H26I3N3O9
- Monoisotopic mass
- 820.8803
- Natural product
- Yes
- 0407-1401
- 0407-1411
- 0407-1412
- 0407-1413
- 0407-1414
- 0407-1415
- 0407-1416
- 71872-7369
- 71872-7370
- 80830-2466
- 80830-2467
- 80830-2468
- 80830-2471
- 80830-2472
- 80830-2473
- Recorded assays
- 1,477
- Active assays
- 8
- Confirmatory
- Other
- Screening
- Contrast Media
Related records
Trials (66)
- A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin
- A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects
- A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects
- A Study of Effect of LY3556050 on Metformin in Healthy Participants
- A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants
- A Study of LY3526318 in Healthy Male Japanese Participants
- A Study of LY3556050 in Healthy Participants
- A Study of LY4515100 in Healthy Participants
- A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
- A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants
- Chest CT Using Low-concentration Iodine Contrast Media
- Clinical and Financial Impact of an Evidenced-Based Adhesive Small Bowel Obstruction Management Protocol
- Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography
- Comparison of CE-DBT and MRI in Patients With Known Breast Lesions
- Comparison of Vascular Access for Radial and Femoral Completion of Diagnostic Cardiac Catheterization
- Computed Tomography Arteriograms (CTA) Volume Dose Reduction Study
- Contrast and Anesthetic Level With Lumbar Erector Spinae Plan (ESP) Block
- Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance
- Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function
- CT TAVR Abdomen Study
In development for (10)
- Acute kidney injury Phase 2
- Breast cancer Phase 1
- Cancer Phase 1
- Fabry disease Phase 1
- HIV infectious disease Phase 1
- Kidney disorder Phase 2
- Kidney failure Phase 1
- Myocardial ischemia Phase 3
- Neoplasm Phase 1
- Type 1 diabetes mellitus Phase 1